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Summary
Glucocorticosteroids are a very effective treatment for asthma and other chronic inflammatory
diseases. However, a small proportion ofpatients is resistant to the therapeutic effects of gluco-
corticoids. Pharmacokinetic and ligand binding studies suggest that the molecular abnormality
in steroid resistance lies distal to nuclear translocation. We have previously reported that there
is a decreased ability of glucocorticoid receptors (GR) to bind to the DNA-binding site in pe-
ripheral blood mononuclear cells (PBMC) after dexamethasone treatment. This reduced DNA
binding was due to a decrease in the number of receptors available rather than an alteration in
affinity for DNA. To study this reduced DNA binding, we examined the ability ofthe nuclear
translocated transcription factors activator protein 1 (AP-1), nuclear factor KB (NF-KB) and cy-
clic AMP response element-binding protein (CREB) to bind to their DNA-binding sites and
to interact with GR in PBMC from patients with steroid-sensitive and steroid-resistant asthma.
There was a significant reduction in the interaction between GR and AP-1 in these steroid-
resistant patients, although interaction with other transcription factors activated in inflamma-
tion (NF-KB and CREB) was unaffected. An increase in the basal levels ofAP-1 DNA binding
was also detected in the nuclei from steroid-resistant asthmatic patients. There were no differ-
ences in the amount of messenger RNA detected for the components of AP-1, c-Fos and
c-Jun, nor in the sequences of these messenger RNAs. These results suggest either that the
ability of the GR to bind to glucocorticoid response elements and AP-1 is altered in steroid-
resistant patients or that increased levels ofAP-1 prevent GR DNA binding, and that this may
be the molecular basis ofresistance to the andinflammatory effect o£ steroids in these cells.
G
lucocorticosteroids are the most effective treatment
for asthma (1), and they have an important place in
the control of other chronic inflammatory or immune dis-
eases. A small proportion ofasthmatic patients is resistant to
the therapeutic effects of glucocorticoids, and the molecu-
lar mechanism for this steroid resistance is unclear (2). A
similar defect in glucocorticoid responsiveness is also re-
ported in patients suffering from other diseases that are
treated by steroid therapy, including rheumatoid arthritis,
systemic lupus erythematosis, and transplantation rejection
(3, 4). Although steroid resistance is relatively rare, under-
standing the molecular mechanisms involved may give im-
portant insights into the mechanism of antiinflammatory
actions of glucocorticoids and into chronic inflammatory
processes . Furthermore, steroid resistance poses a therapeu-
tic problem, as few alternative therapies are available. Ste-
roid resistance has been most extensively studied in asthma,
as the failure here to respond to steroids is more easily doc-
umented than in other inflammatory or immune condi-
tions.
Steroid-resistant (SR)' asthma was first identified by
Schwartz et al. (5), who described six asthmatic patients
whose symptoms failed to improve even with high doses of
oral steroids. Carmichael et al. (6) showed that SR asth-
matic patients tended to be disabled for long periods of
time and present with a stronger family history of asthma
than those who respond to steroids. This corticosteroid re-
sistance is not due to abnormal absorption or clearance of
corticosteroids (2, 7, 8). Furthermore, these patients do not
have features of Addison's disease or elevated plasma corti-
sol concentrations, suggesting that metabolic functions me-
diated by steroids are unaffected. At a cellular level, there is
'Abbreviations used in this paper: AP-1, activator protein l ; CRE, cAMP
response element; CREB, CRE-binding protein; FEVI, forced expiratory
volume in 1 s; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
GR, glucocorticoid receptors; GRE, glucocorticoid response element;
mRNA, messenger RNA; NFKB, nuclear factor KB; RT, reverse tran-
scription; SR, steroid resistant; SS, steroid sensitive; TRE, TPA response
element.
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to corticosteroids, which correlates with clinical resistance
to steroid treatment (8, 9). This functional defect has been
described in blood monocytes (9) and T lymphocytes (8),
and may also be observed in the skin response to topical
steroids (10).
Resistance to the antiinflammatory effects of steroids in
asthma does not appear to be explained by abnormal inter-
action between glucocorticosteroids and glucocorticoid re-
ceptors (GR) . Differences in either affinity or number of
GR is insufficient to account for the observed lack of ste-
roid responses in PBMC or T lymphocytes from SR com-
pared with steroid-sensitive (SS) asthmatic patients, and the
GR-binding characteristics are similar to those reported in
normal asthma (8, 9) . This suggests that the major defect in
steroid resistance lies beyond the point at which the GR
translocates to the nucleus. Recent studies have shown that
there is a reduced enhancement of GR binding to DNA after
60 min ofdexamethasone treatment in vitro in SR patients
(11) and that this reduced capacity is not due to any changes
in the primary sequence of the GR in these patients (12) .
The molecular basis of glucocorticoid action has been
extensively studied. Glucocorticoids enter the cell and bind
to an inactive cytosolic GR, which rapidly translocates to
the nucleus. Within the nucleus the complex binds as a
dimer to specific sites on DNA, termed glucocorticoid re-
sponse elements (GREs), upstream of the promoter region
in SR genes. Binding of the steroid-GR complex to the
GRE enhances or represses transcription of the target gene
(13). The activated translocated GR may also interact with
other transcription factors, such as activator protein 1 (AP-
1), nuclear factor KB (NF-KB), and cAMP response ele-
ment-binding protein (CREB) by a direct proteinprotein
interaction, thus modulating an effect that they would oth-
erwise have on gene transcription (14) . An interaction be-
tween the proinflammatory transcription factor AP-1,
which is a heterodimer of Fos and Jun oncoproteins, and
GR has been demonstrated in cultured cells (15), in human
lung (16), and in human PBMC (17), and may be an im-
portant aspect of the antiinflammatory effect of steroids
(14). NF-KB can also form protein-protein interactions
with GR (16, 18), and this prevention ofNF-KB activation
of gene expression by GR may underlie the mechanism of
steroid action on the messenger RNA (mRNA) of many
cytokines (14). An interaction between GR and CREB has
also been described in various cell types (17, 19) .
Glucocorticoids exert effects on expression of a wide va-
riety of genes, including those for cytokines, receptors, and
enzymes, but the absolute and relative importance ofany of
these to the therapeutic response in asthma is not yet clear.
Many of the important antiinflammatory effects of steroids
appear to be mediated via a reduction in gene transcription,
and this may involve an interaction between GR and AP-1
or NF-KB . This may be of particular relevance in chronic
inflammatory diseases since cytokine- and protein kinase
C-induced activation of transcription factors involved in
mediating chronic inflammatory events at a transcriptional
level may be inhibited by steroids (14) .
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We have tested the possibility that the reduced capacity
of GR to bind to GRE is due to an abnormal interaction
with other transcription factors. Using electrophoretic mo-
bility shift assays, we investigated the effect of steroids on
the DNA binding of transcription factors that may be acti-
vated in chronic inflammation, including AP-1, NF-KB,
and CREB .
Materials and Methods
Patients.
￿
All asthmatic subjects were defined by a history of
episodic wheezing and by a >15% increase in forced expiratory
volume in 1 s (FEVI) after inhaling a bronchodilator (400 N.g al-
buterol). SR patients were classified as showing <5% improve-
ment in lung function after 2 wk of treatment with 40 mg oral
prednisolone per day and have previously been documented to
have PBMC with reduced responsiveness to steroids in vitro (11) .
SS patients had >15% improvement in FEV, after oral predniso-
lone (40 mg dailyfor 2 wk) . The severity ofairway obstruction in
both groups of patients was similar, and the bronchodilator re-
sponses to albuterol indicated that both groups had reversible air-
ways obstruction, consistent with the diagnosis of asthma (Table
1). None ofthe subjects studied had taken oral steroids for at least
l mo before study.
Isolation of PBMC.
￿
20 ml ofheparinized peripheral blood was
obtained from each patient, mixed with 4 ml of 6% dextran, and
allowed to separate for 2 h at 20°C. The upper layer, containing
cells other than erythrocytes, was collected, and PBMC were fur-
ther purified from other leukocytes by separation on Ficoll gradi-
ents. Blood was collected from all patients at the same time of
day. After centrifugation at 1,200g for 20 min at 20°C, PBMC
were removed from the interface, washed twice in Hanks' modi-
fied medium, and kept at 4°C until use (9) . The purity of the
PBMC was 95.2 ± 2.2% monocytes, with the remaining cells
lymphocytes, as assessed by May-Grunwald-Giemsa staining.
Electrophoretic Mobility Shift Assays.
￿
Electrophoreticmobility shift
assays provide a means ofmeasuring the amount ofactivated tran-
Table 1 .
￿
Clinical Characteristics ofSS and SR Asthmatic Patients
SS SR Difference
Number
￿
6 7 NS
Mean values ± SEM are shown.
*Albuterol response is the maximum percentage of increase in FEV,
above baseline value after administration of 400 wg albuterol via a me-
tered dose inhaler.
$Prednisolone was given orally for 2wk at 40 mg/d.
Age (yr)
Gender
Atopy
Smokers
46 -!- 5
4 males
2/6
1/6
51 -- 6
3 males
2/7
1/7
NS
NS
NS
NS
FEV1 (% predicted) 76 ± 4 71 ± 3 NS
Albuterol response
(% increase in FEV,)* 34 ± 2 34 ± 4 NS
Prednisolone response
(% increase in FEV,)$ 36 ± 2 3 ± 0.8 P <0.01scription factors within the nucleus capable of binding to their
specific DNA recognition sequence . This is performed by incu-
bating a nuclear extract with a labeled double-strandedDNA rec-
ognition sequence and detecting the bound oligonucleotide by
its retardation in a nondenaturing gel . Equal numbers of cells
(0.51 ± 0.07 X 10-6 , range 0.19-0.88 X 10-6) were incubated
with 1 p.M dexamethasone, 0.1 p,M PMA, or both for 15-min
intervals up to 60 min . Control experiments using cells incubated
in Hanks' medium alone were run in parallel . At every time
point, cells were collected by microcentrifugation and were nu-
clear protein extracted (17) . Cells were gently lysed in 100 RI of
buffer A (10 mM Hepes, 1.5 mM MgC12, 10 mM KCI, 0.5mM
dithiothreitol, 0.1% NP-40) . After centrifugation (<10 s, 14,000 g,
4°C), the nuclear pellet was lysed with 20 N.I ofbufferB (20 mM
Hepes, 1.5 MM MgC1 2 , 0.42mM NaCl, 0.5 mM dithiothreitol,
25% glycerol, 0.5 mM PMSF, 0.2 mM EDTA) . The subsequent
soluble fraction was mixed with 100 p,1 of buffer C (20 mM
Hepes, 50mM KCI, 0.5mM dithiothreitol, 0.5 mM PMSF, 0.2
mM EDTA) . Double-stranded oligonucleotides encoding the con-
sensus target sequence for GRE (5'-TCGACTGTACAGGAT-
GTTCTAGCTACT-), AP-1 (5'-CGCTTGATGAGTCAGC-
CGGAA-), NF-KB (5'-AGTTGAGGGGAC-TTTCCCAGG-)
and CREB (5'-AGAGATTGCCTGACGTCAGAGAGCTAG-)
(Promega, Cambridge, UK) were end labeled using [32P]ATPand
T4 polynucleotide kinase . 1 ILg of nuclear protein from each
sample was preincubated in 25 VI incubation buffer (4% glycerol,
100mM NaCl, 1mMEDTA, 1mM dithiothreitol, 10 mM Tris-
HCI, pH 7.5, 0.8 mg/ml sonicated salmon sperm DNA) for 20
min at 4°C before the addition of50,000 cpm oflabeled oligonu-
cleotide . The incubation was then continued for a further 40 min
at 20 °C. Protein-DNA complexes were separated on 6% poly-
acrylamide gels using 0.25X Tris-Borate-EDTA running buffer .
The retarded band was detected by autoradiography and quanti-
fied by laser densitometry . All band density measurements were
then expressed as a percentage of initial binding. Specificity was
determined by addition of excess unlabeled double-stranded oli-
gonucleotides . Supershift experiments were performed with 10
Rg nuclear protein . Nuclear proteins were incubated with 5 Rg
anti-GR antibody (Cambridge Bioscience Ltd., Cambridge, UK),
anti-c-Fos antibody (Serotec, Oxford, UK), anti-cJun antibody
(Serotec), or anti-p53 antibody (Cambridge Bioscience Ltd.) for
4 h at 4°C before the addition ofunlabeled oligonucleotide . After
a further 40-min incubation at 20°C, complexes were resolved on
6% gels, and the retarded bands were examined . In some cases,
rather than cause a further retardation (supershift) in the retarded
band, the antibodies inhibited DNA binding to the protein-
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DNA complexes .
Isolation ofRNA and PCR Sequencing of GR, c-Fos, and cJun .
RNAwas extractedfrom the cytoplasmofPBMC after detergent
lysis according to the method of Gough (20) . Reverse transcrip-
tion (RT)-generated cDNA encoding for the DNA-binding site
(bp 1393-1605) and T, domain (bp 520-763) ofthe human Gk,
c-Fos (bp 439-791), cJun (bp 5-245), and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) genes were amplified using
PCR. The primers used for amplifying the cDNA were as de-
scribed below and corresponded to the human GR (21), c-Fos
(22), cJun (23), andGAPDH (24) :
GR DBS forward 5'-TGCCTGGTGTGCTCTGATGAA-
reverse 5'-TCCAGGTTCATTCCAGCCTGA-
GR T,
￿
forward 5'-AATAGGTCGACCAGTGTTCCA-
reverse 5'-TCTCATTCGTCTCTTTACCTG
c-Fos
￿
forward 5'-TAAGATGGCTGCAGCCAAATG
reverse 5'-GTCTTCAGCTCCATGCTGATG
cJun
￿
forward 5'-CTGCAAAGATGGAAACGACCT
reverse 5'-GGATTATCAGGCGCTCCAG
GAPDH forward 5'-ATTCCATGGCA000TCAAGGCT-
reverse 5'-TCAGGTCCACCACTGACACGTT-
PCR products were isolated by Geneclean (Stratech, Luton,
UK) according to the manufacturer's instructions . Cyclesequenc-
ing was performed on the purified cDNA using nested primers in
both forward and reverse directions using exo-Pfu Cyclist (Strat-
agene, Cambridge, UK) using 30 cycles (denature 95°C, 30 min ;
anneal 50°C, 30 min ; extension 72°C, 30 min) after an initial
5-min denaturing step at 95°C with 35S-dATP as the label . At the
end of the cycling period, aliquots were loaded onto a 7% se-
quencing gel, and films were exposed at -70oC.
Data Analysis .
￿
All data are expressed as mean ± SEM. Results
betweentreatment groups were compared by analysis ofvariance .
At specific time, results were compared by Wilcoxon's nonpara-
metric analysis . Pvalues of<0.05 were taken as significant.
Results
Measurement of Baseline Levels of GR and AP-1 .
￿
There
was no difference in the amount ofGR DNA binding de-
tected in unstimulated PBMC between SS andSR groups
(1 .25 ±0.2 versus 1 .32 ± 0.18) (Fig. 1) . Thelevels ofAP-1
binding were significantly greater in the SR than in the SS
group (1 .83 ± 0.13 versus 0.77 ± 0.11, P <0.01) (Fig . 2) .
Confirmation that the bands detected were specific forAP-1
Figure 1 .
￿
Comparison of basal GR DNAbinding in nuclei from
10 5 PBMC from SS (n = 5) and SR (n = 4) patients at baseline.
Band density is measured in arbitrary units, and SS and SR samples
are run on the same gels . (A) An electrophoretic mobility shift assay
from 1 N .g nuclear protein from SS and SR patients . The specific
GR-GRE-retarded band is indicated by an arrow . Specificity ofthe
retarded band is shown by loss ofthis band after preincubation with
an excess ofunlabeled oligonucleotide (XS Ago) . (B) The mean val-
ues (-' SEM) ofthe band density ofthe results shown inA.or GR was obtained by the use of excess unlabeled oligo-
nucleotide, which competed out the labeled oligo and pro-
duced a much reduced band density (Figs . 1 and 2) . Further
evidence that these were specific bands was obtained by su-
pershift assays, whereby an anti-GR antibody caused a fur-
ther retardation (supershift) of the specific GP,-GRE com-
plex . Antibodies to c-Fos also produced a retardation ofthe
GR-GRE band, suggesting an interaction between GR
and c-Fos (Fig . 3) . Furthermore, anti-c-Fos, -cJun, and
-GR antibodies produced a supershiftedAP-1 band, which
was not found after incubation with a specific anti-p53 an-
tibody (Fig . 4) .
Effect ofDexamethasone on AP-1, NF-KB and CREB Elec-
trophoretic Mobility Shift Assay . Dexamethasone alone caused
a 52 .4 ± 11 .2% decrease in AP-1 binding at 60 min in SS
patients, which was significantly greater than the reduction
seen in SR patients (15.5 ± 6.4% decrease, P <0.05), sug-
gesting an abnormality in the direct interaction between
GR and AP-1 (Figs . 5 and 6) . The effect of combined
PMA and dexamethasone treatment in SS and SR patients
was to block the inhibitory effect of dexamethasone on
AP-1 levels and return them to baseline levels (+18.3 ±
9.5% in SS patients and -2 .4 ± 26.0% in SR patients) .
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Figure 3 . Supershift experi-
ments to show interaction ofGR
and c-Fos proteins within the
GR-GRE-binding complex
from PBMC . The figure shows
an electrophoretic mobility shift
assay for GR-GRE binding us-
ing 1 [L.g nuclear proteins . The
specific GR-GRE-retarded
band is indicated by an arrow .
Specificity ofthe retarded band is
shown by loss of this band after
preincubation with an excess of
unlabeled oligonucleotide (XS) .
Preincubation with either anti-
GR or anti-c-Fos antibody pro-
duced a further retardation (super-
shift) in the specific GR-GRE
complex.
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Figure 2 .
￿
Comparison of basal AP-1 DNA binding in nu-
clei from 10 5 PBMC from SS (n = 5) and SR (n = 4) patients
at baseline . Band density is measured in arbitrary units, and SS
and SR samples are run on the same gels . (A) An electro-
phoretic mobility shift assay from 1 lLg nuclear protein from
SS andSR patients . The specific AP-1-TPA response element
(TRE)-retarded band is indicated by an arrow . Specificity of
the retarded band is shown by loss of this band after preincuba-
tion with an excess ofunlabeled oligonucleotide (XS ofigo) . (B)
Mean values (± SEM) of the band density ofthe results shown
in A . ** P <0.01 .
The specificity of transcription factor interactions in SS and
SR patients was also examined. In contrast to the reduced
fall in AP-1 activity after dexamethasone in SR patients,
dexamethasone caused an equal reduction in band density
ofNF-KB in both SS (-41 .6 ± 5.6%) and SR (-31 .0 ±
15.4%) patients (Figs . 5 and 6) and a similar reduction in
CREB binding in both groups of patients (-31 .5 ± 5.7%
in SS versus -35.0 ± 9.5% in SR patients) (Figs . 5 and 6) .
The reduction in NF-KB and CREB binding was found at
all times studied and could be abolished, at least in part, by
coincubation with 1 p,M PMA .
Effect ofPMA on AP-1, NF-KB, and CREB Electrophoretic
Mobility Shift Assay . AP-1 binding in cells from SS patients
demonstrated a 168.3 ± 67.2% increase above baseline af-
ter PMA treatment, which was significantly greater than
Figure 4.
￿
Supershift experiments to show interaction of c-Fos, c-Jun,
and GR proteins within the AP-1-TRE-binding complex from PBMC .
The figure shows an electrophoretic mobility shift assay for AP-l-TRE
binding using 1 N,g nuclear proteins . The specific AP-1-TRE-retarded
band is indicated by an arrow . Specificity of the retarded band is shown
by loss of this band after preincubation with an excess o£ unlabeled oligo-
nucleotide (XS AP-1 oligo) but not with an excess of nonspecific oligo
(XS Oct-1 ofgo) . Preincubation with either anti-Fos, anti-Jun, or anti-GR
antibody produced a further retardation (supershift) in the specific GR-
GRE complex . Preincubation with an anti-p53 antibody had no effect on
AP-1-TRE binding .Figure 5 .
￿
Action of dexamethasone (1 N.M) on AP-1, NFKB, and
CREB nuclear binding in PBMC from SS (n = 6) and SR (n = 7) pa-
tients . The upper panel shows the effect of 60-min dexamethasone treat-
ment on binding of 1 ltg nuclear extracts from SS and SR patients to
consensus double-stranded oligonucleotides encoding AP-1 as deter-
mined by electrophoretic mobility shift assays . The specific AP-1-TRE-
retarded band is indicated by an arrow . Specificity of the retarded band is
shown by loss of this band after preincubation with an excess ofunlabeled
oligonucleotide (XS) . The middle panel shows the effect of 60-min dex-
amethasone treatment on binding of 1 k,g nuclear extracts from SS and
SR patients to consensus double-stranded oligonucleotides encoding
NFKB as determined by electrophoretic mobility shift assays . The specific
NFKB-retarded bands are indicated by arrows. Specificity of the retarded
bands is shown by loss ofthese bands after preincubation with an excess of
unlabeled oligonucleotide (XS) . The lower panel shows the effect of 60-
min dexamethasone treatment on binding of 1 Kg nuclear extracts from
SS and SR patients to consensus double-stranded oligonucleotides encod-
ing CREB as determined by electrophoretic mobility shift assays . The
specific CREB-cAMP response element (CRE)-retarded band is indi-
cated by an arrow . Specificity ofthe retarded band is shown by loss ofthis
band after preincubation with an excess ofunlabeled oligonucleotide (XS) .
that seen in SR patients (9.6 ± 18.4% increase, P <0.05 ;
Fig . 7) . PMA produced a similar level of increase in NF-KB
binding in both groups of subjects . SS subjects demon-
strated a 159.3 ± 54.0% increase after 60-min PMA treat-
ment, which was similar to that in SR patients (108.0 ±
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Figure 6 .
￿
Action of dexamethasone (1 1LM) on nuclear transcription
factor binding in PBMC from SS (n = 6) and SR (n = 7) patients . The
effect o£dexamethasone on binding ofnuclear extracts to consensus dou-
ble-stranded oligonucleotides encoding AP-1, NF-KB, and CREB was
determined using electrophoretic mobility shift assays. Mean ± SEM val-
ues at 60 min are shown ; * P <0.05 (Wilcoxon's nonparametric analysis) .
48.6%) . Similarly, there was no significant difference in the
effect ofPMA on the levels ofCREB binding between the
two groups (-7 .8 ± 19.5% in SS versus -32.8 ± 16.8% in
SR patients) (Fig. 7) . PMA produced a 43 ± 4 .4% decrease
in GR binding in cells from SS patients, but a much re-
duced inhibition of binding was found in the SR group
(-15.3 ± 7 .1%, P <0.05) (Fig . 8) .
Sequence Analysis ofGR.
￿
No differences in the amounts
ofGR mRNA were found between the two groups of
subjects by RT-PCR . cDNA sequence analysis ofboth the
DNA-binding site (bp 1393-1605) and the Tt domain (bp
520-763) oftheGR was performed after RT-PCR ampli-
fication ofmRNA extracted from PBMC from all patients .
There were no differences in themRNA sequences of the
DNA-binding domain or in the 'rt domain of the SR pa-
tients compared with the published human cDNA se-
quence . There were also no differences in the amounts or
sequences of the cfos (bp 439-791) or c-jun (bp 5-245)
mRNA orDNA between the SS and SR groups (Fig. 9) .
SS SR
￿
SS SR
￿
SS SR
AP-1 NFKB CREB
SS SR SS SR
￿
SS SR
AP-1 NFxB CREB
Figure 7 .
￿
Action of PMA (0 .1 KM) on nuclear transcription factor
binding inPBMC from SS (n = 6) andSR (n = 7) patients . The effect of
PMA on binding of nuclear extracts to consensus double-stranded oligo-
nucleotides encoding AP-1, NF-KB, and CREB was determined using
electrophoretic mobility shift assays . Mean a' SEM values at 60 min are
shown; * P <0.05 (Wilcoxon's nonparametric analysis) .a
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Figure 8 . Action of PMA (0 .1
1tM) on nuclear transcription factor
binding in PBMC from SS (n = 6)
and SR (n = 7) patients . The effect
ofPMA on binding of nuclear ex-
tracts to consensus double-stranded
oligonucleotides encoding GRE was
determined using electrophoretic
mobility shift assays . Mean ± SEM
values at 60 min are shown; * P
<0.05 (Wilcoxon's nonparametric
analysis) .
Previous studies ofsteroid resistance have failed to dem-
onstrate any major differences in steroid binding or in nu-
clear localization of steroid receptors in peripheral blood
monocytes or lymphocytes to account for the observed
functional lack of responsiveness . A small decrease in GR
affinity has been described in T lymphocytes of some pa-
tients with SR asthma (25), and a similar abnormality has
been induced in healthy asthmatic patients in the presence
of high concentrations of IL-2 and IL-4 (26) . However,
these relatively minor changes in affinity could not account
for the reduced responsiveness to glucocorticoids seen in T
Figure 9.
￿
Basal levels of GR, cfos, and cjun mRNA in PBMC from
SS and SR patients as measured by RT-PCR . The figure shows a repre-
sentative gel of GAPDH and GR, cfos, and cjun RT-PCR products
from PBMC isolated from SS andSR patients at t = 0 .
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cells from these patients (8) . We have recently reported a
reduced ability of the GR to bind DNA after dexametha-
sone treatment in the PBMC of SR asthmatic patients
compared with SS and normal subjects (11) . Our results
cannot be explained by a reduction in the binding between
steroid andGR in the SR patients, since this has previously
been reported to be unaffected in the same patients (9) . We
now report that there was also a significant reduction in the
direct interaction between the transcription factor AP-1
and GR in SR patients, although interaction with two
other transcription factors, CREB and NFKB, was unaf-
fected . Furthermore, there was an increase in the baseline
levels ofAP-1 in PBMC isolated from SR compared with
SS asthmatic patients, indicating that there is increased acti-
vation of this transcription factor, even in cells that are un-
likely to be affected by inflammation in the airways .
These results suggest that, in PBMC from patients with
SR asthma, the decreased ability of the activated nuclear
GR to bind to GRE may be due to a prior interaction of
GR with other transcription factors, such as AP-1, in-
volved in mediating chronic inflammatory responses . For
example, excessive amounts of AP-1, or the formation of
AP-1 with an altered affinity for GR or DNA, would re-
duce the number ofactivated GR within the nucleus avail-
able for binding to GRE . This may lead to reduced effec-
tiveness of the transcription initiation complex in response
to chronic inflammatory signals, such as cytokines . An ab-
normality in interaction between GR and AP-1 may ex-
plain why the steroid resistance appears to be confined to
the andinflammatory or immunomodulatory actions ofste-
roids, rather than to their metabolic actions . Patients with
steroid resistance do not suffer from steroid deficiency,
have normal plasma cortisol concentrations, and show the
normal adrenal suppression in response to exogenous ste-
roids (2) . This is in contrast to the high circulating levels of
cortisol described in the very rare familial primary cortisol
resistance, in which several abnormalities in GR function
have been described, including reduced affinity and num-
bers of GR and reduction in nuclear localization of GR
(27, 28) . Various abnormalities ofGR structure have been
described in this condition (28) .
The molecular mechanisms underlying the abnormal in-
teraction between GR and AP-1 in SR asthma are not yet
clear . A previous study has demonstrated no abnormality in
GR sequence using chemical mutational analysis (12) . The
sequence of theDNA binding domain and the Tt transcrip-
tion-activating domain reported here in the SR patients
appear to be normal, confirming that there is unlikely to be
a structural abnormality in GR in these patients . This is in
contrast to the structural changes in GR reported in pa-
tients with familial glucocorticoid resistance (27) . These
patients differ from those studied here as they have high
circulating cortisol and may have various endocrine abnor-
malities, none of which are present in patients with SR
asthma. We have described an abnormality in the interac-
tion between AP-1 and GR that may indicate a structural
abnormality in the Fos andJun proteins that comprise AP-1 .
However, sequence analysis of cfos and cjun showed noabnormality compared with published sequences of these
proteins. Several Fos- and Jun-related proteins may consti-
tute AP-1, but c-Fos and c-Jun are the most common. Al-
though no direct evidence exists, these results suggest that
there may be some abnormality in the activation of these
proteins, possibly due to an abnormality in the enzymes,
such as Jun kinase (29), that regulate the activity of AP-1 .
Further studies on these enzymes are therefore indicated,
particularly in view of the increased basal activation of
AP-1 in PBMC that have not been exposed to inflamma-
tory signals.
Corticosteroid resistance is not absolute but reflects a
shift in the dose-response curve and tends to be studied by
selecting patients at the extreme end ofthe spectrum ofste-
roid sensitivity (8, 9) . The sensitivity to prednisolone in
vitro ofT lymphocytes from normal subjects is highly vari-
able, with a >10-fold variation in responsiveness (30) . Pre-
sumably, this variability would only become apparent if
these subjects were to develop an inflammatory or immune
disease requiring glucocorticoid therapy, such as asthma or
systemic lupus erythematosis.
Although steroid resistance, as strictly defined by lack of
response to a large dose of oral steroids, is uncommon, elu-
cidation of its mechanism may shed light on the mecha-
nism of action of steroids in inflammatory diseases such as
asthma. There is increasing evidence that the direct interac-
tion between activated GR and the transcription factor
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AP-1 is important in the inhibitory effects of steroids on
cytokine gene transcription (14), and such interactions have
been demonstrated in human lung and PBMC (16, 17).
The finding that the interaction between GR and AP-1 is
abnormal in patients with steroid resistance lends further
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tiinflammatory action of steroids.
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may be of particular relevance, since this could provide a
mechanism for switching off inflammation driven by cy-
tokines known to activate these transcription factors (14) .
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